Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.86
+0.07 (0.03%)
AAPL  260.58
-3.77 (-1.43%)
AMD  203.37
+3.25 (1.62%)
BAC  52.77
-0.59 (-1.11%)
GOOG  303.56
-0.38 (-0.13%)
META  644.78
+1.56 (0.24%)
MSFT  398.46
-1.14 (-0.29%)
NVDA  187.90
-0.08 (-0.04%)
ORCL  156.54
+0.37 (0.24%)
TSLA  411.71
+0.39 (0.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.